Have a feature idea you'd love to see implemented?
Let us know!
ALEC Alector Inc
Price (delayed)
$5.07
Market cap
$493.42M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.8
Enterprise value
$480.44M
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system
Highlights
The debt has contracted by 12% YoY and by 3.8% from the previous quarter
ALEC's gross profit is down by 46% YoY and by 43% from the previous quarter
The revenue has declined by 46% year-on-year and by 43% since the previous quarter
Key stats
What are the main financial stats of ALEC
Market
Valuations
Earnings
Shares outstanding
97.32M
Market cap
$493.42M
Enterprise value
$480.44M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.25
Price to sales (P/S)
8.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.69
Revenue
$55.28M
EBIT
-$157.67M
EBITDA
-$148.58M
Free cash flow
-$217.76M
Per share
Balance sheet
Liquidity
EPS
-$1.8
Free cash flow per share
-$2.25
Book value per share
$1.56
Revenue per share
$0.57
TBVPS
$5.9
Total assets
$570.73M
Total liabilities
$420.16M
Debt
$36.11M
Equity
$150.57M
Working capital
$372.02M
Debt to equity
0.24
Current ratio
3.52
Quick ratio
3.42
Net debt/EBITDA
0.09
Margins
Efficiency
Dividend
EBITDA margin
-268.8%
Gross margin
100%
Net margin
-290.7%
Operating margin
-338.9%
Return on assets
-25.7%
Return on equity
-102.6%
Return on invested capital
-37%
Return on capital employed
-37.3%
Return on sales
-285.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALEC stock price
How has the Alector stock price performed over time
Intraday
0%
1 week
8.57%
1 month
8.8%
1 year
-1.74%
YTD
-36.47%
QTD
8.8%
Financial performance
How have Alector's revenue and profit performed over time
Revenue
$55.28M
Gross profit
$55.28M
Operating income
-$187.35M
Net income
-$160.66M
Gross margin
100%
Net margin
-290.7%
The net margin has plunged by 132% from the previous quarter and by 107% YoY
ALEC's operating margin has dropped by 125% since the previous quarter and by 120% year-on-year
ALEC's gross profit is down by 46% YoY and by 43% from the previous quarter
The revenue has declined by 46% year-on-year and by 43% since the previous quarter
Growth
What is Alector's growth rate over time
Valuation
What is Alector stock price valuation
P/E
N/A
P/B
3.25
P/S
8.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.69
ALEC's EPS is down by 30% from the previous quarter and by 4% YoY
ALEC's P/B is 26% below its 5-year quarterly average of 4.4 and 10% below its last 4 quarters average of 3.6
The equity has decreased by 23% YoY and by 16% QoQ
The stock's price to sales (P/S) is 70% less than its 5-year quarterly average of 29.6 but 34% more than its last 4 quarters average of 6.6
The revenue has declined by 46% year-on-year and by 43% since the previous quarter
Efficiency
How efficient is Alector business performance
ALEC's ROS has plunged by 136% from the previous quarter and by 109% YoY
The return on equity has dropped by 52% year-on-year and by 43% since the previous quarter
The return on invested capital has declined by 41% since the previous quarter and by 39% year-on-year
Alector's ROA has decreased by 40% from the previous quarter and by 38% YoY
Dividends
What is ALEC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALEC.
Financial health
How did Alector financials performed over time
ALEC's total assets is 36% greater than its total liabilities
The quick ratio has contracted by 29% YoY
Alector's current ratio has decreased by 28% YoY
The debt is 76% less than the equity
The equity has decreased by 23% YoY and by 16% QoQ
The debt to equity is up by 14% since the previous quarter and by 14% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.